Stock Ticker

  • Loading stock data...

This info on Agile Therapeutics, Inc. (AGRX) could trigger a massive change in trading

Agile Therapeutics, Inc. (AGRX) has received an average target price from analysts of 4.40 amounting to a recommendation rating of Buy. That comes from 6 different analysts. Perhaps, the driver for that assessment comes from the company’s valuations.

To give a sense of trend, the same data point on the estimate for next year is currently sitting at N/A times earnings. Drilling down a bit further, this quarter, we are looking at an average estimate from analysts for earnings per share level of 6.00. That shift to 4.00 heading into next quarter.

Agile TherapeuticsInc. is a healthcare companywhich engages in the development and commercialization of transdermal patch. Its lead product candidateTwirlaalso known as AG200-15is an investigational low-dosenon-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton,NJ.

Shares of Agile Therapeutics, Inc. (AGRX) last opened at $2.02. More than 17,380,549 shares exchanged hands compared to an average daily volume of 2,506,868 shares. At the current pps, the market capitalization stands at 115.705M.

Investors try to use stocks with high beta values to quickly recoup their investments after sharp market losses. Agile Therapeutics, Inc. (AGRX) currently has a Beta value of 0.98 . Beta is a measurement of a stock’s price fluctuations, which is often called volatility and is used by investors to gauge how quickly a stock’s price will rise or fall. A stock with a beta of greater than 1.0 is riskier and has greater price fluctuations, while stocks with beta values of less than 1.0 are steadier and generally larger companies. Beta is often measured against the S&P; 500 index. An S&P; 500 stock with a beta of 2.0 produced a 20 percent increase in returns during a period of time when the S&P; 500 Index grew only 10 percent. This same measurement also means the stock would lose 20 percent when the market dropped by only 10 percent.

Next, let’s take a look at Agile Therapeutics, Inc current P/E ratio. Agile Therapeutics, Inc. (AGRX) currently has a PE ratio of N/A. PE ratio is an important parameter to look at when trading a stock mostly because it is easy to calculate. There are a couple of ways to calculate PE ratio either by dividing share price by earnings per share or dividing the market cap by net income. It is important to note that the earnings are usually taken from the trailing twelve months (TTM). Nevertheless, P/E tells us how much an investor is willing to pay for $1 of a company’s earnings. The long-term average P/E is around 15, so on average, investors are willing to pay $15 for every dollar of earnings. Another useful way to look at this: Turn the P/E ratio around to look at the E/P ratio, which when expressed as a percentage gives us the earnings yield. For instance: 1/15 gives us an earnings yield of 6.67%.

While we have already looked at Agile Therapeutics, Inc beta and P/E ratio, the EPS cannot be ignored. Agile Therapeutics, Inc EPS for the trailing twelve months was -0.3870. Traders and investors often use earnings per share (TTM) to determine a company’s profitability for the past year. So in essence, EPS is the amount of a company’s net income per share of common stock. Earnings per share equal the company’s net income less any dividends paid on preferred stock divided by the weighted average number of common stock shares outstanding during the year. Agile Therapeutics, Inc is estimated to release its next earnings report on Oct 28, 2019. It would be interesting to see how the earnings fair out considering the recent developments.

Published by Steve Hackney

Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.

Recent Stories

Sponsored Content

Sign Up To Get Our Latest Stocks Alerts